PT107433B - Processo de redução e controlo do tamanho de partícula - Google Patents

Processo de redução e controlo do tamanho de partícula

Info

Publication number
PT107433B
PT107433B PT10743314A PT10743314A PT107433B PT 107433 B PT107433 B PT 107433B PT 10743314 A PT10743314 A PT 10743314A PT 10743314 A PT10743314 A PT 10743314A PT 107433 B PT107433 B PT 107433B
Authority
PT
Portugal
Prior art keywords
particle size
size reduction
control process
solvent
aging
Prior art date
Application number
PT10743314A
Other languages
English (en)
Other versions
PT107433A (pt
Inventor
Villax Peter
Sobral Luís
Temtem Marcio
Cancela Silva Constança
Costa Eunice
Original Assignee
Hovione Farm S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hovione Farm S A filed Critical Hovione Farm S A
Priority to PT10743314A priority Critical patent/PT107433B/pt
Priority to EP15702834.1A priority patent/EP3096738B1/en
Priority to ES15702834T priority patent/ES2702643T3/es
Priority to DK15702834.1T priority patent/DK3096738T3/en
Priority to CA2938071A priority patent/CA2938071A1/en
Priority to PCT/GB2015/050186 priority patent/WO2015114320A1/en
Priority to AU2015212618A priority patent/AU2015212618B2/en
Priority to HUE15702834A priority patent/HUE041329T2/hu
Priority to JP2016549143A priority patent/JP6499187B2/ja
Priority to US15/115,193 priority patent/US10328027B2/en
Publication of PT107433A publication Critical patent/PT107433A/pt
Priority to IL246989A priority patent/IL246989A0/en
Publication of PT107433B publication Critical patent/PT107433B/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Thermistors And Varistors (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

NOVO PROCESSO AJUSTÁVEL EM ESCALA PARA CONTROLO DO TAMANHO DE PARTÍCULA E DA DISTRIBUIÇÃO DE TAMANHO DE PARTÍCULA, COMPREENDENDO CINCO PASSOS: (II) PREPARAÇÃO DA SUSPENSÃO NUMA MISTURA DE SOLVENTES EM QUE O API E / OU EXCIPIENTE É PARCIALMENTE SOLÚVEL NUM DOS SOLVENTES; (II) REDUÇÃO DO TAMANHO DAS PARTÍCULAS DA SUSPENSÃO; (III) ENVELHECIMENTO; (IV) INTERRUPÇÃO DO ENVELHECIMENTO POR REMOÇÃO DE SOLVENTE; E (V) OPCIONALMENTE, UM PASSO DE ISOLAMENTO DOS INGREDIENTES PROCESSADOS NA FORMA DE PÓ.
PT10743314A 2014-01-28 2014-01-28 Processo de redução e controlo do tamanho de partícula PT107433B (pt)

Priority Applications (11)

Application Number Priority Date Filing Date Title
PT10743314A PT107433B (pt) 2014-01-28 2014-01-28 Processo de redução e controlo do tamanho de partícula
PCT/GB2015/050186 WO2015114320A1 (en) 2014-01-28 2015-01-27 Assisted particle size reduction process
ES15702834T ES2702643T3 (es) 2014-01-28 2015-01-27 Procedimiento asistido de reducción del tamaño de la partícula
DK15702834.1T DK3096738T3 (en) 2014-01-28 2015-01-27 Method of Assisted Particle Size Reduction
CA2938071A CA2938071A1 (en) 2014-01-28 2015-01-27 Assisted particle size reduction process
EP15702834.1A EP3096738B1 (en) 2014-01-28 2015-01-27 Assisted particle size reduction process
AU2015212618A AU2015212618B2 (en) 2014-01-28 2015-01-27 Assisted particle size reduction process
HUE15702834A HUE041329T2 (hu) 2014-01-28 2015-01-27 Támogatott részecskeméret-csökkentési eljárás
JP2016549143A JP6499187B2 (ja) 2014-01-28 2015-01-27 支援された粒子径低減方法
US15/115,193 US10328027B2 (en) 2014-01-28 2015-01-27 Assisted particle size reduction process
IL246989A IL246989A0 (en) 2014-01-28 2016-07-28 A controlled process to reduce particle size

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PT10743314A PT107433B (pt) 2014-01-28 2014-01-28 Processo de redução e controlo do tamanho de partícula

Publications (2)

Publication Number Publication Date
PT107433A PT107433A (pt) 2015-07-28
PT107433B true PT107433B (pt) 2018-12-04

Family

ID=52450514

Family Applications (1)

Application Number Title Priority Date Filing Date
PT10743314A PT107433B (pt) 2014-01-28 2014-01-28 Processo de redução e controlo do tamanho de partícula

Country Status (11)

Country Link
US (1) US10328027B2 (pt)
EP (1) EP3096738B1 (pt)
JP (1) JP6499187B2 (pt)
AU (1) AU2015212618B2 (pt)
CA (1) CA2938071A1 (pt)
DK (1) DK3096738T3 (pt)
ES (1) ES2702643T3 (pt)
HU (1) HUE041329T2 (pt)
IL (1) IL246989A0 (pt)
PT (1) PT107433B (pt)
WO (1) WO2015114320A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7700076B2 (en) 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
JP2006505583A (ja) 2002-10-25 2006-02-16 フォーミックス エルティーディー． 化粧剤および医薬用フォーム
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US9439857B2 (en) 2007-11-30 2016-09-13 Foamix Pharmaceuticals Ltd. Foam containing benzoyl peroxide
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769625C (en) 2009-07-29 2017-04-11 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
MX359879B (es) 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Composiciones tópicas de tetraciclina.
PT108368B (pt) 2015-03-31 2018-11-05 Hovione Farm S A Produção contínua de partículas
PT109117B (pt) 2016-01-28 2019-02-01 Hovione Farm Sa Complexação de ingredientes ativos farmacêuticos
IL285928B2 (en) 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
MX377365B (es) 2016-09-08 2025-03-10 Journey Medical Corp Composiciones y métodos para tratar rosácea y acné.
CN110361307B (zh) * 2019-08-15 2022-04-01 安徽工程大学 一种利用粒度分布特征值判断稻米新陈度的方法
EP3868842B1 (en) 2020-02-19 2023-06-07 University of Limerick Particle coating method
GB202002325D0 (en) 2020-02-19 2020-04-01 Univ Limerick Particle coating method
US12485133B2 (en) 2021-02-04 2025-12-02 Hovione Scientia Limited Inhaled ivermectin
CA3221280A1 (en) 2021-06-03 2022-12-08 Arcadia Medicine, Inc. Enantiomeric entactogen compositions and methods of their use

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379459B1 (en) * 2000-10-24 2002-04-30 The United States Of America As Represented By The Secretary Of The Interior Crystallization of powders having uniform particle sizes by Ostwald ripening at large levels of supersaturation
US20100099885A1 (en) * 2006-10-03 2010-04-22 Mukesh Kumar Sharma Process for the preparation of form i and form ii of ritonavir
WO2011131947A2 (en) * 2010-04-21 2011-10-27 Hovione Inter Ltd A process for particle processing of active pharmaceutical ingredients

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008411D0 (en) * 2000-04-05 2000-05-24 Vectura Ltd Pharmaceutical preparations and their manufacture
GB0016040D0 (en) 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
JP5197564B2 (ja) * 2006-03-14 2013-05-15 メルク・シャープ・エンド・ドーム・コーポレイション 微細粉砕及び微細な種での結晶化により有機結晶微細粒子組成物を製造する方法
EP2050437A1 (en) 2007-10-15 2009-04-22 Laboratoires SMB Improved pharmaceutical dry powder compositions for inhalation.
BRPI0820745A2 (pt) * 2007-12-13 2015-06-16 Novartis Ag Compostos orgânicos
PT106237B (pt) * 2012-03-30 2015-03-19 Hovione Farmaci Ncia S A Produção de partículas substancialmente monodispersas utilizando moagem e separação por membranas

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6379459B1 (en) * 2000-10-24 2002-04-30 The United States Of America As Represented By The Secretary Of The Interior Crystallization of powders having uniform particle sizes by Ostwald ripening at large levels of supersaturation
US20100099885A1 (en) * 2006-10-03 2010-04-22 Mukesh Kumar Sharma Process for the preparation of form i and form ii of ritonavir
WO2011131947A2 (en) * 2010-04-21 2011-10-27 Hovione Inter Ltd A process for particle processing of active pharmaceutical ingredients

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LINDFORS L. ET AL: "Amorphous drug nanosuspensions. 1. Inhibition of Ostwald ripening in Langmuir 22(3)", PÁGINAS 906-10, 31 January 2006 (2006-01-31) *

Also Published As

Publication number Publication date
IL246989A0 (en) 2016-09-29
HUE041329T2 (hu) 2019-05-28
AU2015212618A1 (en) 2016-09-15
AU2015212618B2 (en) 2018-08-02
WO2015114320A1 (en) 2015-08-06
US20160346206A1 (en) 2016-12-01
EP3096738B1 (en) 2018-09-26
CA2938071A1 (en) 2015-08-06
PT107433A (pt) 2015-07-28
JP6499187B2 (ja) 2019-04-10
US10328027B2 (en) 2019-06-25
JP2017504637A (ja) 2017-02-09
DK3096738T3 (en) 2019-01-21
EP3096738A1 (en) 2016-11-30
ES2702643T3 (es) 2019-03-04

Similar Documents

Publication Publication Date Title
PT107433B (pt) Processo de redução e controlo do tamanho de partícula
EP3240551A4 (en) Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
EP3219668A4 (en) Method for large-scale preparation of bulky graphene
EP3137002A4 (en) Methods, devices, and manufacture of the devices for musculoskeletal reconstructive surgery
EP3294289A4 (en) Use of cannabis to treat fibromyalgia, methods and compositions thereof
EP3261640A4 (en) 5ht agonists for treating disorders
EP3243303A4 (en) Network virtualization for network infrastructure
EP3301777A4 (en) Stability inspecting method for tying inverter to grid, and inverter
EP3134130A4 (en) Compositions and methods to treating hemoglobinopathies
EP3156364A4 (en) Method and device for producing sodium borohydride
EP3190085A4 (en) Method for preparing graphene by using high speed homogenization pretreatment and high pressure homogenization
SG10201900574SA (en) Virtual currency conversion device, method and computer program
EP3130107A4 (en) Apparatus and method for low latency switching
BR112016018654A2 (pt) Composições de silicato estabilizadas e seu uso como composições antiperspirantes
BR112015028257A2 (pt) composição farmacêutica de baixa dose, método para tratar sobrecarga de ferro crônica, método para tratar toxicidade por chumbo, processo para preparar uma composição farmacêutica de baixa dose e processo
EP3151951B8 (en) Methods, devices, systems and kits for preparing compositions for care and repair of varicose veins
CL2016000038A1 (es) Piraxolo-piridinaminas sustituidas
EP3156043A4 (en) A-gel-intermediate composition, and production method for a-gel-containing o/w emulsion cosmetic using said composition
BR112016028316A2 (pt) composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
EP3198843A4 (en) Method and system for serving virtual desktop to client
EP3142699A4 (en) Compositions and methods for treating metabolic disorders
EP3133490A4 (en) Virtual desktop processing method and device, and virtual desktop server
EP3204426A4 (en) Compositions and methods for treating viral hemorrhagic fever
EP3174991A4 (en) Methods, compositions, and kits for analysis of structurally diverse complex lipids
EP3294735B8 (en) Inhibitors of influenza viruses replication

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 20150625

FG3A Patent granted, date of granting

Effective date: 20181130